When: Positive CMS CGM coverage decision

Then: One of 3 confirmations required for add-back toward full size

When: Daily close below $104.00 on volume >7M (confluence failure + realized momentum)

Then: Escalate to Underweight

When: Q3 earnings miss with operating margin compression below 14%

Then: Escalate to Underweight

When: MACD stays negative for 4+ weeks with no histogram contraction

Then: Escalate to Underweight

When: Pre-announcement EPS warning or FY guidance cut

Then: Escalate to Underweight

Trim 10-15% with tight invalidation at 105.22; do not add new positions; hold core for dividend income while awaiting technical resolution

• Confluence zone at 105.22 (200 SMA) to 106.55 (lower Bollinger band) within $1.50 represents structural floor with institutional memory
• Aggressive trim of 30-40% at 110.65-111.89 resistance layer is premature given multi-factor support below
• Stop at 102.50 ($5.83 below current, over 2x ATR) is excessive for 0.58 beta name; conservative stop should be 1-1.5 ATR at 104.00-105.50
• Five consecutive lower highs and negative MACD histogram confirm broken momentum but do not warrant panic trimming at support
• 2.32% yield on Dividend Aristocrat provides meaningful income while awaiting technical resolution
• Free cash flow of 7.4 billion with four years of deleveraging supports holding case
• Aggressive 30-40% trim would force chasing back higher if confluence zone holds
• Do not initiate new positions despite constructive catalysts (FDA Libre Duo, LAA closure CE mark) without price action confirmation
• Conditional HOLD with predefined exit is correct; passive HOLD with no defined exit is just hope
• Resolution expected in 2-3 weeks; asymmetric protection with structured patience

→ vs aggressive: Stop at 102.50 (2+ ATR) is excessive for 0.58 beta name; sets up getting stopped out on noise before bounce

→ vs aggressive: Trimming 30-40% into multi-factor confluence zone hands shares to dip buyers at worst possible spot

→ vs neutral: HOLD without predefined exit criteria is passive inaction; if price breaks 200 SMA, swift move to 100.68 materializes without protective action

→ vs neutral: Pure HOLD with no defined invalidation level is hope disguised as patience, not risk management

Trim 20% now at 108.33, with option to add another 10% trim on failed rally at 110.65-111.89; maintain 70% core position; stop at 103.50-104.00

• Momentum is broken (RSI rolling from 78 to 47, price below 10 EMA at 110.65, five consecutive lower highs) but aggressive analyst's trim plan requires price to reclaim resistance before execution—conditional optimism rather than actionable strategy
• Confluence zone is rock solid: 200 SMA at 105.22, lower Bollinger at 106.55, July breakout level, and 50 SMA rising at 104.21 stacked within tight band
• Dividend yield of 2.32% on Dividend Aristocrat with seven years of consecutive raises provides real income while waiting; 0.58 beta makes yield meaningful in total return calculation
• Forward PE of 17.86 is supported by tax rate normalization (2025 rate 22.9% vs artificially low 14.1% in 2023), not heroic revenue growth; TTM PE of 35 using heroic 96% EPS growth estimate is misleading
• Macro environment is supportive: 93% probability of no Fed cuts in 2026, 6% recession odds, sticky inflation—capital rotates into healthcare defensives in this regime
• Zero Reddit activity means no retail bid but also no retail-driven euphoria to unwind; sentiment backdrop is constructive but thin, neutral not bearish
• Aggressive analyst's 102.50 stop contradicts their own confluence thesis by sitting below support they claim has teeth; stop should be below 105.22 or they should be trimming more
• Conservative analyst's 10-15% trim is 'passive hope with a fig leaf of risk control'—token action that accomplishes neither meaningful risk reduction nor conviction-based positioning
• Setup is a range trade (support 105.22-106.55, resistance 110.65-111.89) likely to play out over weeks, not a decisive directional bet
• Core position captures optionality on FDA Libre Duo commercial rollout and LAA encroachment into Boston Scientific's WATCHMAN franchise
• Breakdown invalidation trigger: close below 104 with volume escalates risk reduction; reclaim of 10 EMA with RSI above 50 would trigger adding back

→ vs aggressive: Trim plan requires price to reclaim 110.65-111.89 before execution but price is currently at 108.33 and below the 10 EMA it has failed to reclaim for five sessions; plan requires setup to invalidate itself first

→ vs aggressive: 102.50 stop contradicts the confluence thesis by sitting below support the analyst claims has teeth—either the 200 SMA at 105.22 matters or it does not; cannot bet against the structure you claim to respect

→ vs conservative: 10-15% trim is risk management theater that accomplishes neither meaningful risk reduction nor conviction-based positioning; cannot use confluence support to justify holding and broken momentum to justify trimming while splitting the difference

→ vs conservative: 104.00-105.50 stop sits inside the confluence zone and will get chopped out on any intraweek test of support even if the zone ultimately holds

→ vs aggressive: Using TTM PE of 35 with 96% EPS growth estimate requirement misleads; market trades on forward PE of 17.86 which is based on tax normalization already played out, not heroic assumptions